Dr. Coleman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
407 E 70th St
3rd Floor
New York, NY 10021Phone+1 212-517-5900Fax+1 212-734-9238- Is this information wrong?
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1967 - 1968
Emory University School of MedicineResidency, Internal Medicine, 1963 - 1965
Virginia Commonwealth University School of MedicineClass of 1963
Certifications & Licensure
NY State Medical License 1968 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- Top Doctors: New York Metro Area Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
- A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsZanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu, Jason M Melear, Morton Coleman, Charles M Farber, Jonah Shulman, Emily H Mantovan...> ;Ejhaem. 2023 Feb 1
- 13 citationsA phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.Paolo Strati, Morton Coleman, Rebecca Champion, Shuo Ma, Caterina Patti, Moshe Y Levy, Izidore S Lossos, Praveen Ramakrishnan Geethakumari, Selay Lam, Roser Calvo, Kar...> ;British Journal of Haematology. 2022 Oct 1
- 34 citationsThe MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Morton Coleman, Catherine Thie...> ;Clinical Cancer Research. 2021 Sep 15
- Join now to see all
Journal Articles
- Five-Year Follow-up of Lenalidomide plus Rituximab as Initial Treatment for Mantle Cell LymphomaJia Ruan, Jakub Svoboda, John P Leonard, Sonali M Smith, Morton Coleman, Richard R Furman, Blood
- Oral Lymphomatoid Papulosis Type C: A Diagnostic Pitfall, Often Confused with T-cell Lymphoma☆Jennifer P Toyohara, Morton Coleman, Ziv Schwartz, ScienceDirect
Abstracts/Posters
- Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain AmyloidosisMorton Coleman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Harnessing the Epichaperome As a Therapeutic Approach in Multiple MyelomaMorton Coleman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple MyelomaMorton Coleman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).2019 ASCO Annual Meeting - 6/1/2019
- Chairman, Lymphoma & Myeloma 2013: An International Congress on Hematologic MalignanciesWaldorf-Astoria Hotel, New York, New York - 10/24/2013
- Moderator, Expert Reviews in Hematology 2014: 20th Annual Network of Oncology Clinicians & Researchers (NOCR) MeetingImedex, Las Vegas, Nevada - 2/27/2014
Press Mentions
Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)November 3rd, 2020
Dr. Furman on Acalabrutinib Monotherapy in CLLFebruary 10th, 2020
42-Month Follow-up Data of Acalabrutinib Monotherapy in R/R CLLDecember 9th, 2019- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
New York-Presbyterian HospitalNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
